Compare HMN & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HMN | PVLA |
|---|---|---|
| Founded | 1945 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.0B |
| IPO Year | 1996 | 2013 |
| Metric | HMN | PVLA |
|---|---|---|
| Price | $51.20 | $145.75 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 15 |
| Target Price | $47.33 | ★ $171.87 |
| AVG Volume (30 Days) | ★ 225.3K | 144.2K |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | ★ 3.05% | N/A |
| EPS Growth | ★ 57.26 | 52.62 |
| EPS | ★ 2.01 | N/A |
| Revenue | ★ $1,701,400,000.00 | $42,810,000.00 |
| Revenue This Year | $6.91 | N/A |
| Revenue Next Year | $3.41 | $104,350.18 |
| P/E Ratio | $25.17 | ★ N/A |
| Revenue Growth | 6.66 | ★ 65.28 |
| 52 Week Low | $41.29 | $49.81 |
| 52 Week High | $55.56 | $161.38 |
| Indicator | HMN | PVLA |
|---|---|---|
| Relative Strength Index (RSI) | 48.31 | 47.44 |
| Support Level | $50.60 | $135.30 |
| Resistance Level | $53.34 | $147.47 |
| Average True Range (ATR) | 1.39 | 7.20 |
| MACD | -0.22 | -1.81 |
| Stochastic Oscillator | 25.13 | 34.58 |
Horace Mann Educators Corp is a diversified insurance holding company that markets and underwrites personal lines of property and casualty insurance, retirement annuities, and life insurance. The company's property and casualty operations focus on automobile and homeowner insurance, while the retirement annuities are tax-qualified products. Horace Mann Educators markets its products to kindergarten through 12th-grade teachers, administrators, and other employees of public schools and their families. The Company conducts and manages its business in four reporting segments: (1) Property & Casualty, (2) Life & Retirement, (3) Supplemental & Group Benefits and (4) Corporate & Other.
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.